We've put some small files called cookies on your device to make our site work.
We'd also like to use analytics cookies. These send information about how our site is used to a service called Google Analytics. We use this information to improve our site.
Let us know if this is OK. We'll use a cookie to save your choice. You canĀ read more about our cookies before you choose.
Clinical commissioning policy: Trametinib in recurrent or progressive low grade serous ovarian cancer (adults)
Trametinib is recommended to be available off-label as a routine commissioning treatment option for adults with recurrent or progressive low grade serous ovarian cancer within the criteria set out in this document.